Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sutent + Irinotecan + Cetuximab in Stage IV Colorectal Cancer
NCT00361244Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2006
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in colorectal cancer (CRC), sponsored by Massachusetts General Hospital. Primary endpoints: Maximum Tolerated Dose at 1 year and Objective Response Rate. Started Jul 2006; status: terminated.
02
Drugs
sunitinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00361244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00361244.